MENU

公表論文等

Publication Paper

2020年

  1. Nakamaru R, Nakagami H, Hayashi H, Sun J, Tenma A, Yamamoto K, Shimamura M, Morishita R, Rakugi H. A novel angiotensin Ⅱ peptide vaccine without an adjuvant in mice. J Hypertens. (Accepted)

  2. Yoshida S, Nakagami H, Hayashi H, Ikeda Y, Sun J, Tenma A, Tomioka H, Kawano T, Shimamura M, Morishita R, Rakugi H. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat. Commun. 2020 May 18;11(1):2482.

2019年

  1. Hironori Nakagami, Ryuichi Morishita, Shuko Takeda, Munehisa Shimamura, Tomohiro Kawano, Kouji Wakayama, Tatsuhiko Azegami, Hiroshi Itoh, Jiao Sun, Hiroki Hayashi, Kunihiko Yamashita, Hideki Tomioka, Akiko Tenma, Makoto Sakaguchi. Therapeutic Vaccines as Novel Immunotherapy. Springer. 2019 Dec.

  2. Tenma A,Nakagami H,Tomioka H,Sakaguchi M,Ide R,Koriyama H,Hayashi H,Shimamura M, Rakugi H,Morishita.,AJP001, a novel helper T-cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine. FASEB Bioadv. 2019 Nov 22;1(12):760-772.

  3. Nakagami H, Sugimoto K, Ishikawa T, Koshizaka M, Fujimoto T, Kiyohara E, Hayashi M, Nakagawa Y, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Ebihara T, Nakamura A, Nishikawa M, Yao XJ, Hanaoka H, Yokote K, Rakugi H. Investigator-initiated clinical study of a functional peptide, SR-0379, for limb ulcers of patients with Werner syndrome as a pilot study. Geriatr Gerontol Int. 2019

2018年

  1. Nakagami H, Sugimoto K, Ishikawa T, Fujimoto T, Yamaoka T, Hayashi M, Kiyohara E, Ando H, Terabe Y, Takami Y, Yamamoto K, Takeya Y, Takemoto M, Koshizaka M, Ebihara T, Nakamura A, Nishikawa M, Yao XJ, Hanaoka H, Katayama I, Yokote K, Rakugi H. Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial. NPJ Aging Mech Dis. 2018;4:2

2017年

  1. 天満 昭子 「機能性ペプチドの実用化を目指した抗体誘導ペプチドの開発」能動免疫療法シンポジウム、2017.2.22、東京<口演>

  2. Nakagami H, Yamaoka T, Hayashi M, Tanemura A, Takeya Y, Kurinami H, Sugimoto K, Nakamura A, Tomono K, Tamai K, Katayama I, Rakugi H, Kaneda Y. Physician-initiated first-in-human clinical study using a novel angiogenic peptide, AG30/5C, for patients with severe limb ulcers. Geriatr Gerontol Int. 2017 May

  3. ペプチド医薬品のスクリーニング・安定化・製剤技術 株式会社技術情報協会

2015年

  1. 天満 昭子 「創傷治癒効果と抗菌効果を併せ持つペプチドの創生」バイオインダストリー シーエムシー出版 Vol.32, No.3, 49-56, 2015.3

  2. 冨岡 英樹 「抗菌ペプチドの創傷治癒治療薬としての開発」エンドトキシン・自然免疫研究 医学図書出版(株) Vol.18, 13-18, 2015.9

  3. 天満 昭子「アンチエイジング効果と抗菌作用を併せ持つ機能性ペプチド素材の開発」シーエムシー出版  機能性ペプチドの開発最前線

2014年

  1. 天満 昭子 「プラットフォームテクノロジーによるアンチエイジングペプチドの創生」第14回日本抗加齢医学会総会、2014.6.6、大阪<ポスター>

  2. Pang Z, Nakagami H, Osako M, Koriyama H, Nakagami F, Tomioka H, Shimamura M, Kurinami H, Takami Y, Morishita R, Rakugi H. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceedings of the National Academy of Sciences USA 2014;111:E1256-1263.

  3. Tomioka H, Nakagami H, Tenma A, Saito Y, Kaga T, Kanamori T, Tamura N, Tomono K, Kaneda Y, Morishita R. Novel anti-microbial peptide SR-0379 accelerates wound healing via the PI3 kinase/akt/mTOR pathway. PLoS One 2014;9:e92597.

2012年

  1. Nakagami H, Nishikawa T, Tamura N, Maeda A, Hibino H, Mochizuki M, Shimosato T, Moriya T, Morishita R, Tamai K, Tomono K, Kaneda Y. Modification of a Novel Angiogenic Peptide, AG30, for the Development of Novel Therapeutic Agents. J Cell Mel Med 2012 Jul;16(7):1629-1639

Translate »